Regeneron: Strong Growth Potential and Innovation Commitment Amidst Challenges

Leerink Partners analyst David Risinger has maintained their bullish stance on REGN stock, giving a Buy rating yesterday.

David Risinger has given his Buy rating due to a combination of factors that highlight Regeneron’s potential for growth despite some current challenges. The stock appears attractive with a price-to-earnings ratio of 14 times the estimated earnings per share for 2026 and a projected five-year earnings growth rate of 12%. This valuation is considered favorable compared to the broader large-cap group median.
Additionally, Regeneron’s research and development investment as a percentage of enterprise value is significantly higher than the industry median, indicating a strong commitment to innovation. Although there are uncertainties surrounding the Eylea franchise, including delayed FDA approval for a new product format, the company’s pipeline remains promising with upcoming developments expected for several key drug candidates. These factors collectively support the Buy rating, as they suggest potential for future value creation.

According to TipRanks, Risinger is a 5-star analyst with an average return of 7.5% and a 52.54% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Sanofi, and AnaptysBio.

In another report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $804.00 price target.